A study to investigate DYSPORT® for the treatment of subjects with loss of bladder control and involuntary urination as a result of spinal cord injury or multiple sclerosis

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-000507-44

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

• To assess the efficacy of two Dysport® doses (600 units (U) and 800 U), compared to placebo in reducing UI from Baseline to Week 6 following the first investigational medicinal product (IMP) administration.


Critère d'inclusion

  • Urinary incontinence caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosis